Tocilizumab – a disease-modulating treatment for thyroid associated ophthalmopathy?
Orbit · 2025
DOI: 10.1080/01676830.2025.2452181 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Orbit, 2025. Verfasst von K Farde und 1 weiteren Autor:innen. Beteiligte Einrichtung: VO Kirurgi, St Erik Eye Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: To analyze Tocilizumab (TCZ, an interleukin 6 inhibitor) as a second-line treatment for thyroid-associated ophthalmopathy (TAO). METHODS: In this retrospective observational study, the charts of patients with moderately severe to severe TAO who received intravenous Tocilizumab as a second-line treatment 2020-2023 were reviewed. RESULTS: Twenty-three patients were enrolled in the study. At the follow-up visit 24 weeks after the initiation of treatment, 14 out of 22 patients (63.6%, one missing data) had a reduction of proptosis of 2 mm or more. The mean proptosis decreased from 21.07 (±3.23) to 19.18 (±2.52) mm in the right eye (RE) and from 20.61 (±3.12) to 19.95 (±2.81) mm in the left eye (LE). Twenty patients (87%) also showed a reduction of the clinical activity score (CAS) of at least two points with a mean decrease from 5.22 (±1.53) pre-treatment to 2.09 (±1.38) post-treatment points. The median patient total follow-up time after treatment was ten (range 6-26) months. The comparisons reached strong significance between pre-treatment and 24 weeks, as well as pre-treatment and final visit assessments for both proptosis and clinical activity scores. Serum TRAb levels also dropped significantly, and only two patients needed re-treatment with TCZ. Improvement of diplopia did not reach statistical significance. CONCLUSIONS: Intravenous Tocilizumab as a second-line treatment for TAO led to a significant improvement of proptosis and CAS at 24 weeks follow-up, with a sustained effect over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- VO Kirurgi, St Erik Eye Hospital, Stockholm, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- VO Medicin, St Erik Eye Hospital, Stockholm, Sweden.
Zitieren
APA
Farde, K., & Träisk, F. (2025). Tocilizumab – a disease-modulating treatment for thyroid associated ophthalmopathy?. Orbit. https://doi.org/10.1080/01676830.2025.2452181
Vancouver
Farde K, Träisk F. Tocilizumab – a disease-modulating treatment for thyroid associated ophthalmopathy?. Orbit. 2025. doi:10.1080/01676830.2025.2452181
BibTeX
@article{Farde2025,
author = {Farde, K and Träisk, F},
title = {Tocilizumab – a disease-modulating treatment for thyroid associated ophthalmopathy?},
journal = {Orbit},
year = {2025},
doi = {10.1080/01676830.2025.2452181}
}
EUVIMED